Contemporary Management of Metastatic Pancreatic Cancer
Symposium
Symposium

Contemporary Management of Metastatic Pancreatic Cancer

Exploring the Nuances of Patient Care Across the Disease Continuum

Not a member of My prIME? Join now for instant access.

Meeting Overview

Enhance your understanding of the treatment options available for patients with metastatic pancreatic cancer (mPCA), including a focus on supportive care measures. The improvement of outcomes in this patient population are modest and most develop resistance to chemotherapy. This meeting will provide you insights into the emerging treatment approaches for targeting the pancreatic tumor microenvironment and strategies to enhance immune response. In addition to didactic lectures, real-life clinical scenarios will be presented and examined during a faculty panel discussion.

Satellite symposium held in conjunction with the ESMO 20th World Congress on Gastrointestinal Cancer. This symposium content is not an official part of the World Congress scientific program, nor is it organized or endorsed by Imedex.

Date and Location

Saturday, 23 June 2018
13.25 – 14.55

Room: 113-115
Centre de Convencions Internacional de Barcelona (CCIB)
Plaça de Willy Brandt 11-14
Barcelona, Spain

Date/Time

Date/Time

Saturday, 23 June 2018
13.25 – 14.55

Location

Location

Barcelona, Spain

IME

IME

Saturday, June 23

13.25 Welcome and introduction
Julien Taïeb, MD, PhD
13.30 Pancreatic cancer brain teasers
Julien Taïeb, MD, PhD
13.35 Considering treatment options for advanced PCA in light of new data: What is the optimal treatment sequence?
Teresa Macarulla, MD, PhD
13.52 Overcoming treatment resistance in PCA: Update on emerging strategies targeting the tumor microenvironment
Eileen O’Reilly, MD
14.09 Supportive care across the disease continuum: An important adjunct to systemic therapy
Giuseppe Aprile, MD
14.26 Clinical challenges in PCA: Interactive case-based discussion
Julien Taïeb, MD, PhD
14.51 prIME Points™
Julien Taïeb, MD, PhD
14.55 Adjourn

    Chair

  • Julien Taïeb, MD, PhD Georges Pompidou European Hospital
    Paris, France
  • Faculty

  • Giuseppe Aprile, MDSan Bortolo General Hospital
    Vicenza, Italy
  • Teresa Macarulla, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Eileen O’Reilly, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States

This educational activity is designed for medical oncologists, gastroenterologists, and other healthcare providers outside of the United States who are involved in the management of patients with PCA.

After successful completion of this educational activity, participants should be able to:

  • Select the most appropriate treatment sequence for patients with advanced pancreatic ductal adenocarcinoma, taking into consideration patient and disease characteristics
  • Describe emerging treatment approaches for targeting the PCA microenvironment, including stromal depleting agents and strategies to enhance immune response
  • Evaluate and appropriately use supportive care measures in patients with PCA

This educational activity is supported by a grant from Shire.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.